Arrowhead's REDEMPLO Gains German Approval for Rare Metabolic Disorder Treatment
Event summary
- Arrowhead Pharmaceuticals' REDEMPLO (plozasiran) approved in Germany for Familial Chylomicronaemia Syndrome (FCS) treatment.
- First EU country to list REDEMPLO in Lauer-Taxe® database for prescription and reimbursement.
- Treatment can be prescribed based on clinical symptoms or genetic test, unlike competitors requiring genetic confirmation.
- Approval based on Phase 3 PALISADE study showing efficacy in reducing triglycerides.
- Subcutaneous injection administered once every three months.
The big picture
Arrowhead's approval in Germany marks a strategic milestone in expanding access to RNAi therapeutics for rare metabolic disorders. The ability to prescribe REDEMPLO based on clinical symptoms broadens its potential patient base, addressing a significant unmet need in FCS treatment. This approval positions Arrowhead to potentially lead in the rare disease space, leveraging its TRiM™ platform for future therapeutic developments.
What we're watching
- Market Expansion
- How quickly Arrowhead can secure approvals in other European countries.
- Competitive Positioning
- Whether REDEMPLO's clinical diagnosis option can capture market share from competitors.
- Reimbursement Dynamics
- The impact of Lauer-Taxe® listing on adoption rates and revenue growth.